170 related articles for article (PubMed ID: 34162140)
1. Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy.
Bahrololoumi Shapourabadi M; Momburg F; Roohvand F; Jarahian M; Mohajel N; Arashkia A; Hajari Taheri F; Abbasalipour M; Azadmanesh K
Int Immunopharmacol; 2021 Jul; 96():107762. PubMed ID: 34162140
[TBL] [Abstract][Full Text] [Related]
2. Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase.
Jarahian M; Watzl C; Fournier P; Arnold A; Djandji D; Zahedi S; Cerwenka A; Paschen A; Schirrmacher V; Momburg F
J Virol; 2009 Aug; 83(16):8108-21. PubMed ID: 19515783
[TBL] [Abstract][Full Text] [Related]
3. Killing Effects of IFN R
Liang S; Lin X; Liang Y; Song D; Zhang L; Fan X
Anat Rec (Hoboken); 2019 Oct; 302(10):1718-1725. PubMed ID: 31120191
[TBL] [Abstract][Full Text] [Related]
4. Expression and Purification of a Bispecific Antibody against CD16 and Hemagglutinin Neuraminidase (HN) in
Bahrololoumi Shapourabadi M; Roohvand F; Arashkia A; Mohajel N; Abdoli S; Shahosseini Z; Momburg F; Jarahian M; Abolhassani M; Azadmanesh K
Rep Biochem Mol Biol; 2020 Apr; 9(1):50-57. PubMed ID: 32821751
[TBL] [Abstract][Full Text] [Related]
5. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antibodies increase T-cell stimulatory capacity in vitro of human autologous virus-modified tumor vaccine.
Haas C; Strauss G; Moldenhauer G; Iorio RM; Schirrmacher V
Clin Cancer Res; 1998 Mar; 4(3):721-30. PubMed ID: 9533542
[TBL] [Abstract][Full Text] [Related]
7. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
[TBL] [Abstract][Full Text] [Related]
8. Factor VIII moiety of recombinant Factor VIII Fc fusion protein impacts Fc effector function and CD16
Lagassé HAD; Ou J; Sauna ZE; Golding B
Front Immunol; 2024; 15():1341013. PubMed ID: 38655263
[TBL] [Abstract][Full Text] [Related]
9. Functional Domain Order of an Anti-EGFR × Anti-CD16 Bispecific Diabody Involving NK Cell Activation.
Kuwahara A; Nagai K; Nakanishi T; Kumagai I; Asano R
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33255436
[TBL] [Abstract][Full Text] [Related]
10. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.
Gleason MK; Verneris MR; Todhunter DA; Zhang B; McCullar V; Zhou SX; Panoskaltsis-Mortari A; Weiner LM; Vallera DA; Miller JS
Mol Cancer Ther; 2012 Dec; 11(12):2674-84. PubMed ID: 23075808
[TBL] [Abstract][Full Text] [Related]
11. Factor VIII-Fc Activates Natural Killer Cells
Lagassé HAD; Hopkins LB; Jankowski W; Jacquemin MG; Sauna ZE; Golding B
Front Immunol; 2021; 12():692157. PubMed ID: 34262568
[TBL] [Abstract][Full Text] [Related]
12. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
13. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.
Srivastava S; Pelloso D; Feng H; Voiles L; Lewis D; Haskova Z; Whitacre M; Trulli S; Chen YJ; Toso J; Jonak ZL; Chang HC; Robertson MJ
Cancer Immunol Immunother; 2013 Jun; 62(6):1073-82. PubMed ID: 23604103
[TBL] [Abstract][Full Text] [Related]
14. Tribody [(HER2)
Oberg HH; Kellner C; Gonnermann D; Sebens S; Bauerschlag D; Gramatzki M; Kabelitz D; Peipp M; Wesch D
Front Immunol; 2018; 9():814. PubMed ID: 29725336
[TBL] [Abstract][Full Text] [Related]
15. The hemagglutinin-neuramidinase protein of Newcastle disease virus upregulates expression of the TRAIL gene in murine natural killer cells through the activation of Syk and NF-κB.
Liang Y; Song DZ; Liang S; Zhang ZF; Gao LX; Fan XH
PLoS One; 2017; 12(6):e0178746. PubMed ID: 28614370
[TBL] [Abstract][Full Text] [Related]
16. Activation of cloned human natural killer cells via Fc gamma RIII.
Werfel T; Uciechowski P; Tetteroo PA; Kurrle R; Deicher H; Schmidt RE
J Immunol; 1989 Feb; 142(4):1102-6. PubMed ID: 2464637
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies.
Haas C; Schirrmacher V
Cancer Immunol Immunother; 1996 Nov; 43(3):190-4. PubMed ID: 9001573
[TBL] [Abstract][Full Text] [Related]
19. TRAIL is involved in the tumoricidal activity of mouse natural killer cells stimulated by Newcastle disease virus in vitro.
Song DZ; Liang Y; Xiao Q; Yin J; Gong JL; Lai ZP; Zhang ZF; Gao LX; Fan XH
Anat Rec (Hoboken); 2013 Oct; 296(10):1552-60. PubMed ID: 23959779
[TBL] [Abstract][Full Text] [Related]
20. Rapid and potent induction of cell death and loss of NK cell cytotoxicity against oral tumors by F(ab')2 fragment of anti-CD16 antibody.
Jewett A; Teruel A; Romero M; Head C; Cacalano N
Cancer Immunol Immunother; 2008 Jul; 57(7):1053-66. PubMed ID: 18188563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
